The Beauty Health Company (NASDAQ:SKIN) Shares Sold by Cohen Capital Management Inc.

Cohen Capital Management Inc. lessened its holdings in shares of The Beauty Health Company (NASDAQ:SKIN) by 10.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 150,613 shares of the company’s stock after selling 16,705 shares during the quarter. Cohen Capital Management Inc. owned about 0.11% of Beauty Health worth $468,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Raymond James & Associates bought a new stake in shares of Beauty Health in the 4th quarter worth $31,000. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Beauty Health in the 4th quarter worth $31,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Beauty Health in the 3rd quarter worth $90,000. Kestra Private Wealth Services LLC raised its stake in shares of Beauty Health by 40.8% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 15,887 shares of the company’s stock worth $96,000 after buying an additional 4,600 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of Beauty Health in the 3rd quarter worth $97,000. Institutional investors and hedge funds own 93.26% of the company’s stock.

Beauty Health Stock Performance

NASDAQ:SKIN remained flat at $3.27 during trading hours on Monday. The company had a trading volume of 1,408,904 shares, compared to its average volume of 2,619,190. The stock has a market cap of $403.61 million, a price-to-earnings ratio of -4.25 and a beta of 1.01. The Beauty Health Company has a 52-week low of $1.35 and a 52-week high of $13.06. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.28 and a current ratio of 6.07. The stock has a fifty day moving average price of $3.65 and a two-hundred day moving average price of $3.45.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The firm had revenue of $96.80 million for the quarter, compared to analyst estimates of $87.22 million. Beauty Health had a negative return on equity of 18.85% and a negative net margin of 25.65%. Beauty Health’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 earnings per share. On average, equities research analysts predict that The Beauty Health Company will post -0.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. TD Cowen boosted their price objective on Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a research note on Wednesday, March 13th. Stifel Nicolaus reaffirmed a “hold” rating and set a $4.00 target price (up from $3.00) on shares of Beauty Health in a research report on Wednesday, March 13th. DA Davidson reaffirmed a “buy” rating and set a $5.00 target price on shares of Beauty Health in a research report on Friday, March 15th. Piper Sandler reaffirmed an “underweight” rating and set a $3.00 target price (up from $2.00) on shares of Beauty Health in a research report on Wednesday, March 13th. Finally, Canaccord Genuity Group boosted their target price on Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research report on Thursday, March 14th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.50.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.